Pathway-specific polygenic risk scores as predictors of amyloid-β deposition and cognitive function in a sample at increased risk for Alzheimer’s disease

Manuscript Number: 

16-0195R1

Author(s): 
Sanjay Asthana, Barbara B. Bendlin, Kaj Blennow, Cynthia M. Carlsson, Bradley T. Christian, Burcu F. Darst, Corinne D. Engelman, Bruce P. Hermann, Kirk J. Hogan, Sterling C. Johnson, Rebecca L. Koscik, Rachel A. Krause, Jennifer M. Oh, Ozioma C. Okonkwo, Annie M. Racine, Mark A. Sager, Henrik Zetterberg

Disclosures

Sanjay Asthana

  • Grants
    • Agency: 
      Lundbeck Pharmaceuticals
      Dates: 
      3/16/2014 - Present
    • Agency: 
      Toyoma Chemical
      Dates: 
      11/21/2013 - Present
    • Agency: 
      Merck Pharmaceuticals
      Dates: 
      3/31/2014 - Present

Barbara B. Bendlin

  • Nothing to Disclose

Kaj Blennow

  • Consulting Fees:
    Eli Lilly, Fujirebio Europe, IBL International, Novartis, Roche Diagnostics

Cynthia M. Carlsson

  • Grants
    • Agency: 
      NIH and Lilly co-sponsor the A4 Study for which I am site PI at UW-Madison
      Dates: 
      8/2014-present

Bradley T. Christian

  • Patents/Royalties
    Patent for tomosynthesis in breast imaging. It is unrelated to the work reported in this manuscript.

Burcu F. Darst

  • Nothing to Disclose

Corinne D. Engelman

  • Nothing to Disclose

Bruce P. Hermann

  • Nothing to Disclose

Kirk J. Hogan

  • Nothing to Disclose

Sterling C. Johnson

  • Nothing to Disclose

Rebecca L. Koscik

  • Nothing to Disclose

Rachel A. Krause

  • Nothing to Disclose

Jennifer M. Oh

  • Nothing to Disclose

Ozioma C. Okonkwo

  • Nothing to Disclose

Annie M. Racine

  • Nothing to Disclose

Mark A. Sager

  • Nothing to Disclose

Henrik Zetterberg

  • Nothing to Disclose